Skip to main content
Full access
Treatment in Psychiatry
Published Online: 1 June 2010

Medication Treatment of Different Types of Alcoholism

Abstract

Abstract

Alcoholism remains a serious cause of morbidity and mortality despite progress through neurobiological research in identifying new pharmacological strategies for its treatment. Drugs that affect neural pathways that modulate the activity of the cortico-mesolimbic dopamine system have been shown to alter drinking behavior, presumably because this dopaminergic system is closely associated with rewarding behavior. Ondansetron, naltrexone, topiramate, and baclofen are examples. Subtyping alcoholism in adults into an early-onset type, with chronic symptoms and a strong biological predisposition to the disease, and a late-onset type, typically brought on by psychosocial triggers and associated with mood symptoms, may help in the selection of optimal therapy. Emerging adults with binge drinking patterns also might be aided by selective treatments. Although preliminary work on the pharmacogenetics of alcoholism and its treatment has been promising, the assignment to treatment still depends on clinical assessment. Brief behavioral interventions that encourage the patient to set goals for a reduction in heavy drinking or abstinence also are part of optimal therapy.

Formats available

You can view the full content in the following formats:

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 630 - 639
PubMed: 20516163

History

Received: 11 October 2008
Accepted: 5 January 2010
Published online: 1 June 2010
Published in print: June 2010

Authors

Details

Bankole A. Johnson, D.Sc., M.D.

Notes

Received Oct. 11, 2008; revision received Dec. 23, 2009; accepted Jan. 5, 2010 (doi: 10.1176/appi.ajp.2010.08101500). From the Department of Psychiatry and Neurobehavioral Sciences, University of Virginia. Address correspondence and reprint requests to Dr. Johnson, Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, P.O. Box 800623, Charlottesville, VA 22908-0623; [email protected] (e-mail).

Competing Interests

Dr. Johnson has served in a consulting capacity to ADial Pharmaceuticals, Eli Lilly, Johnson & Johnson (Ortho-McNeil Janssen Scientific Affairs LLC), Psychological Education Publishing Company, Organon, and Transcept Pharmaceuticals.

Funding Information

Supported by grants 2 R01 AA010522-13, 7 R01 AA010522-12, 5 R01 AA012964-06, 5 R01 AA013964-05, 5 R01 AA014628-04, and 7 U10 AA011776-10 from the National Institute on Alcohol Abuse and Alcoholism, and NIH grant M01 RR00847 through the University of Virginia General Clinical Research Center.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Full Text

View Full Text

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share